Cutler Group LP Atossa Therapeutics, Inc. Put Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2022 Feb 07, 2023	SELL	$0.5 - $1.01 $50 - $101	-100 Reduced 0.52%	19,200 $38,000
Q3 2022 Oct 25, 2022	BUY	$0.82 - $1.14 $82 - $113	100 Added 0.52%	19,300 $34,000
Q2 2022 Aug 04, 2022	SELL	$0.85 - $1.28 $1,870 - $2,816	-2,200 Reduced 10.28%	19,200 $30,000
Q1 2022 Apr 14, 2022	SELL	$1.11 - $1.74 $26,862 - $42,108	-24,200 Reduced 53.07%	21,400 $30,000
Q4 2021 Jan 18, 2022	SELL	$1.6 - $3.27 $50,400 - $103,005	-31,500 Reduced 40.86%	45,600 $65,000

Q3 2021 Oct 26, 2021	SELL	$2.89 - $6.4 $689,843 - $1.53 Million	-238,700 Reduced 75.59%	77,100 $84,000
Q2 2021 Jul 19, 2021	BUY	$1.52 - $8.62 $466,488 - $2.65 Million	306,900 Added 3448.31%	315,800 $202,000
Q1 2021 Apr 26, 2021	BUY	$0.92 - $4.33 $5,796 - $27,279	6,300 Added 242.31%	8,900 $37,000
Q3 2020 Oct 27, 2020	SELL	$1.98 - $4.35 $11,088 - $24,359	-5,600 Reduced 68.29%	2,600 $0
Q2 2020 Jul 22, 2020	BUY	$1.04 - $4.05 $8,528 - $33,210	8,200 New	8,200 $1,000

19.3M

95K

82.4K

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $147M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.